Catalyst ligands

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

62937-45-5, General procedure: A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119-91-5,2,2′-Biquinoline,as a common compound, the synthetic route is as follows.

Under argon atmosphere, 1,2-bis(diphenylphosphino)benzene (91.7 mg, 0.205 mmol) was added to 5 mL of the suspension of silver(I) tetrafluoroborate (40.0 mg, 0.205 mmol) in dry dichloromethane, and the mixture was stirred at room temperature for one hour. Then, 2,2′-biquinoline (52.7 mg, 0.205 mmol) was added to the reaction solution, which was stirred at room temperature for another one hour. The pale yellow reaction solution was filtrated, and the filtrate was concentrated, subjected to recrystallization by slow diffusion of chloroform-ether, and dried to provide 171 mg of the pale yellow solid complex. The result of elemental analysis for the obtained complex is shown in Table 2-2, and the composition ratio of the complex was obtained. The present complex corresponds to the above composition formula (5).

119-91-5, 119-91-5 2,2′-Biquinoline 8412, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Sumitomo Chemical Company, Limited; EP2360162; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

33454-82-9, Lithium trifluoromethanesulfonate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: 1-Methoxy/1,6-dimethoxy pyridinium bromide (1.0 equiv./1.784×10-3 mmol) and 1.03 equiv. inorganic salt (NaBF4, K4PF6, and LiCF3SO3) are mixed with 10 mL of deionized water at room temperature with stirring for about 1 h to give anion exchanged products 3-8., 33454-82-9

The synthetic route of 33454-82-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Manikandan, Chitrarasu; Ganesan, Kilivelu; Synthetic Communications; vol. 44; 23; (2014); p. 3362 – 3367;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step B1: (9R)-1-[3,5-Bis(trifluoromethyl)benzyl]cinchonan-1-ium-9-ol bromide [table-us-00013-en] d Materials FW Mass Volume mol Equiv. (g/mL) Cinchonidine 294.39 6.1 kg 20.72 1 3,5-Bis(trifluoro-methyl)benzylbromide 307.03 7.0 kg 4.19 L 22.8 1.1 1.671 IPA 66 L (0217) 3,5-Bis(trifluoromethyl)benzyl bromide (7.0 kg) was dissolved in isopropyl alcohol (IPA, 60 L) at 23 C. under nitrogen. To the stirred light yellow solution was added cinchonidine (6.1 kg) in portions over 20 minutes (no exotherm), affording a white slurry. Additional IPA (6 L) was added to rinse all the cinchonidine down into the reaction mixture. The slurry was heated to gentle reflux, reaching an internal temperature of 80-82.5 C. The mixture became less viscous while being heated, and once the temperature had reached 60.6 C. the last of the cinchonidine had dissolved to give a dark yellow solution. Once the mixture had reached gentle reflux, the reaction was seeded by the addition of (9R)-1-[3,5-Bis(trifluoromethyl)benzyl]cinchonan-1-ium-9-ol bromide (62.3 g, 0.104 mol, 0.5 mol % relative to cinchonidine starting material), which led to the immediate precipitation of the product. The mixture was maintained at gentle reflux for 3.5 h, then heating was ceased and the orange slurry was allowed to cool to room temperature (21 C.) with stirring overnight. (0218) After cooling, the mixture was filtered, and the pink product cake was washed with fresh IPA (1¡Á10 L then 1¡Á30 L) to remove unreacted starting materials and most of the color, and dried under vacuum with a nitrogen sweep to afford the title product.

485-71-2, The synthetic route of 485-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Merck Sharp & Dohme Corp.; Bell, Ian M.; Fraley, Mark; Gallicchio, Steven N.; Ginnetti, Anthony; Mitchell, Helen J.; Paone, Daniel V.; Staas, Donnette D.; Wang, Cheng; Zartman, C. Blair; Stevenson, Heather E.; (30 pag.)US9499541; (2016); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.40000-20-2,5-Bromo-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

To a mixture of 18 (274 mg, 0.63 mmol), 15 (163 mg,0.63 mmol), Pd(PPh3)Cl2 (22 mg, 5 molpercent) and anhyd. K2CO3(261 mg, 1.89 mmol) was added dry DMSO (5 mL) and degassedfor 15 min. The mixture was then heated at 100 C for 24 h. Aftercooling, H2O (10 mL) was added to the reaction mixture and theprecipitate that had formed was collected and washed with H2O(20 mL), EtOH (20 mL), acetone (5 mL) and allowed to dry under vacuum to provide 6 as a tan-colored solid (240 mg, 70percent): mp220 C dec; 1H NMR (500 MHz,CDCl3) d 9.23 (m, 2H), 8.85 (s, 2H),8.75 (d, 2H, J = 4.01 Hz), 8.71 (d, 2H, J = 9.16 Hz), 8.32 (m, 2H),8.10 (d, 2H, J = 8.02 Hz), 7.91 (dt, 2H, J = 8.02, 1.72 Hz), 7.83 (s,1H), 7.69 (m, 3H), 7.63 (m, 1H), 7.38 (m, 2H); 13C NMR(125 MHz, DMSO-d6) d 156.4, 155.4, 150.8, 150.4, 149.9, 149.5,146.4, 145.7, 140.1, 138.1, 137.9, 137.6, 136.9, 134.6, 131.5,128.4, 127.8, 127.6, 127.5, 125.2, 124.3, 123.9, 121.5, 118.5.

40000-20-2, As the paragraph descriping shows that 40000-20-2 is playing an increasingly important role.

Reference£º
Article; Nair, Neelima V.; Zhou, Rongwei; Thummel, Randolph P.; Inorganica Chimica Acta; vol. 454; (2017); p. 27 – 39;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33454-82-9,Lithium trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.

The mixture of 1 (1.11 g, 4.3 mmol) and LiOTf (0.81 g, 5.1 mmol) in dryCH3CN was stirred at room tempareture. After stirring 18 h, the reaction mixturewas diluted with CH2Cl2. Filteration and removal of solvent under reducedpuressure afforded IL-tag 2 as a white solid in 88% yield (1.41 g, 3.8 mmol).(4-(hydroxymethyl)benzyl)methylpiperidinium trifluoromethane sulfonate(2). TLC (MeOH/CH3COOH 10:1): Rf 0.39. 1H NMR (MeOD-d4, 600 MHz)delta 7.56 (d, J = 8.4 Hz, 2 H), 7.53 (d, J = 8.4 Hz, 2 H), 4.70 (s, 2 H), 4.57 (s, 2 H),3.43 (td, J = 13.2, 4.2 Hz, 2 H), 3.36 (dt, J = 12.6, 4.2 Hz, 2 H), 3.00 (s, 3 H),2.05 – 1.94 (m, 4 H), 1.83 – 1.78 (m, 1 H) , 1.71 – 1.64 (m, 1 H). 13C NMR(MeOD-d4, 150 MHz) delta 146.0, 134.2, 128.4, 127.1, 121.9 (q, J = 316.4 Hz), 68.9,64.4, 61.9, 47.2, 22.2, 21.1. HRMS (ESI) m/z calcd for C14H22NO [M-TfO-]+,220.1696; found, 220.1688.

33454-82-9, 33454-82-9 Lithium trifluoromethanesulfonate 3664839, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sasaki, Norihiko; Nokami, Toshiki; Itoh, Toshiyuki; Chemistry Letters; vol. 46; 5; (2017); p. 683 – 685;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.128143-89-5,4′-Chloro-2,2′:6′,2”-terpyridine,as a common compound, the synthetic route is as follows.

Compound M (18.00 g, 34.25 mmol) and compound N (12.23 g, 34.25 mmol) were completely dissolved in 300 ml of tetrahydrofuran in a 500 ml round-bottomed flask under nitrogen atmosphere, and 2M aqueous potassium carbonate solution (150 ml)Tetrakis- (triphenylphosphine) palladium (1.18 g, 1.02 mmol) was added thereto, followed by heating and stirring at 75C for 3 hours. The temperature was lowered to room temperature (23 ¡À 5 C), the water layer was removed, dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and recrystallized from 120 ml of ethyl acetate to obtain Compound 10 (16.9 g, 74%

128143-89-5, 128143-89-5 4′-Chloro-2,2′:6′,2”-terpyridine 667748, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; LG CHEMICAL LTD; LG Chem, Ltd.; YANG JUNG HOON; Yang Jeong-hun; LEE DONG HOON; Lee Dong-hun; HUH JUNG OH; Huh Jeong-o; JANG BOON JAE; Jang Bun-jae; HEO DONG UK; Huh Dong-uk; HAN MI YEON; Han Mi-yeon; YUN HEE KYUNG; Yoon Hui-gyeong; (47 pag.)KR2019/9704; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10581-12-1,Tetramethylammonium acetate,as a common compound, the synthetic route is as follows.

A solution of H3F3ST (300mg, 0.39mmol) dissolved in 6mL of anhydrous dimethylacetamide (DMA) was treated with solid NaH (28mg, 1.2mmol). The mixture was stirred until gas evolution ceased. Fe(OAc)2 (68mg, 0.39mmol) and NMe4OAc (52mg, 0.39mmol), were added to the cloudy white reaction, and the solution was stirred. After 3h, 5mL of Et2O was added to the yellow solution to aid the precipitation of NaOAc. The reaction mixture was filtered through a medium porosity glass-fritted funnel to remove the insoluble species and the filtrate was dried under vacuum. The resulting pale yellow solid was redissolved in 5mL of acetonitrile (MeCN), stirred for 20min, and filtered using a fine porosity glass-fritted funnel. The filtrate was concentrated under vacuum to ca. 1mL and treated with Et2O (10mL) then pentane (40mL) to precipitate a pale yellow solid. The pale yellow solid was collected on a medium porosity glass-fritted funnel and dried under vacuum to give 182mg (91%) of product. FTIR (KBr disc, cm-1, selected bands): 3413, 3046, 2964, 2902, 2861, 1608, 1490, 1403, 1326, 1263, 1134, 1062, 976, 821, 710, 622, 605. MS (ES-, m/z): Exact mass calcd for C27H24N4O6S3F9Fe: 823.0, Found: 823.1.

10581-12-1, As the paragraph descriping shows that 10581-12-1 is playing an increasingly important role.

Reference£º
Article; Lau, Nathanael; Ziller, Joseph W.; Borovik; Polyhedron; vol. 85; (2015); p. 777 – 782;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

54761-04-5, Ytterbium(III) trifluoromethanesulfonate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

54761-04-5, General procedure: A mixture of Ce(OTf)3 (0.1388g, 0.2mmol) and C12H8N2 (phen) (0.005g) was dissolved in a mixture of CH3CN (10ml) and DMF (three drops). After the mixture was stirred for 1h, the ligand L (0.2752g, 0.8mmol) was added to this mixture. Stirring was continued for 4h at ambient temperature. After this time, any insoluble residues were removed by filtration, and the filtrate was evaporated slowly at room temperature for about one month to yield colorless crystalline products.

54761-04-5 Ytterbium(III) trifluoromethanesulfonate 2733225, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Xu, Shan; Liu, Min; Yang, Yu-Ping; Jiang, Yu-Han; Li, Zhong-Feng; Jin, Qiong-Hua; Wang, Xin; Xue, Xiao-Nan; Polyhedron; vol. 87; (2014); p. 293 – 301;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1126-58-5,1-(2-Hydrazinyl-2-oxoethyl)pyridin-1-ium chloride,as a common compound, the synthetic route is as follows.

General procedure: To a mixture of the corresponding bis(isatin) 1-8 (5 mmol) and Girard?s reagent (2.5 mmol) in 7 mL of absolute ethanol were added three drops of trifluoroacetic acid. The reaction mixture was refluxed for 2 h. After spontaneous cooling of the solution to room temperature, the formed precipitate was filtered off, washed with absolute diethyl ether and dried in vacuum (12 mmHg)., 1126-58-5

The synthetic route of 1126-58-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Bogdanov; Zaripova; Mustafina; Voloshina; Sapunova; Kulik; Mironov; Russian Journal of General Chemistry; vol. 89; 7; (2019); p. 1368 – 1376; Zh. Obshch. Khim.; vol. 89; 7; (2019); p. 1004 – 1012,9;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI